Optimal duration of treatment for HCV genotype 1 infection in slow responders: A meta-analysis

Hepatitis Monthly

Volumn 11, Issue 8, 2011, Pages 612-619

  Alavian, Seyed Moayed ^a   Tabatabaei, Seyed Vahid ^a   Behnava, Bita ^a   Mahboobi, Nastaran ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Genotype; Hepatitis C virus; Treatments

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ASTHENIA; CHRONIC HEPATITIS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; MALE; META ANALYSIS; NEUTROPENIA; PROCESS OPTIMIZATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 80052569206     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.721     Document Type: Review

References (57)

1. Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. Hepat Mon. 2005;5(3):77-82.
2. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIV. J Clin Virol. 2001;22(1):11-29.
3. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 (Suppl 1):74-81.
4. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35-S46.
5. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407-13.
6. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8(2):192-9.
7. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96(9):975-81.
8. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-13.
9. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17(4):287-92.
10. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55(1):69-75.
11. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011;106(3):452-8.
12. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47(6):1884-93.
13. Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther. 2009;14(8):1139-48.
14. Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493-501.
15. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50.
16. Borenstein M, Hedges LV. Introduction to Meta-Analysis. the first ed. UK: John Wiley & Sons, Ltd; 2009.
17. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. 2nd ed. New York: Oxford University Press; 2000.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
19. Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-analyses. Stata J. 2009;9(2):197-210.
20. Heathcote J. Retreatment of chronic hepatitis C: who and how? Liver Int. 2009;29(Suppl 1):49-56.
21. Dieterich DT, Rizzetto M, Manns MP. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin. J Viral Hepat. 2009;16(12):833-43.
22. Nakamura J, Toyabe SI, Aoyagi Y, Akazawa K. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat. 2008;15(4):293-9.
23. Pearlman BL. Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. World J Gastroenterol. 2008;14(23):3621-7.
24. Tarantino G, Craxi A. Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review. Liver Int. 2009;29(Suppl 1):31-8.
25. Poordad FF. Review article: the role of rapid virologic response in determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther. 2010;31(12):1251-67.
26. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. 2008;46(1):78-84.
27. Pearlman BL. Chronic hepatitis C therapy: changing the rules of duration. Clin Gastroenterol Hepatol. 2006;4(8):963-71.
28. Nguyen-Khac E, Capron D, Castelain S, Francois C, Braillon A. Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype? Eur J Intern Med. 2007;18(7):510-5.
29. Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol. 2007;47(4):580-7.
30. Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology. 2003;37(5):1226-7.
31. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47(10):1260-9.
32. August-Jorg BSE, Borovicka J, Dufour JF, Gonvers JJ, Henz S, Hermann R, et al. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly. 2003;133(33-34):455-60.
33. Ikeda H, Suzuki M, Okuse C, Yamada N, Okamoto M, Kobayashi M, et al. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res. 2009;39(8):753-9.
34. Hezode C. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepato Gastro. 2008;15(3):252-3.
35. Yao GB, Ji YY, Xu DZ, Gao J, Wu XH, Zhang QB, et al. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: A randomized prospective study comparing two dose schedules in Chinese patients. Hepato Gastro. 1999;46(26):1059-64.
36. Yao G, Ji Y, Yang M, Xu D, Gao J, Wu X, et al. Long-term efficacy of recombinant Interferon alpha 2a in the treatment of chronic hepatitis C: A randomized prospective study comparing two dose schedules in Chinese patients. Chinese Med J. 1998;111(10):922-6.
37. Piccinino F, Felaco FM, Sagnelli E, Aprea L, Messina V, Pasquale G, et al. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment. Res Virol. 1998;149(5):283-91.
38. Fattovich G, Zagni I, Fornaciari G, Minola E, Fabris P, Boccia S, et al. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. J Viral Hepat. 2003;10(2):111-7.
39. Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, et al. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol. 2003;38(2):158-63.
40. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIVinfected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23(8):972-82.
41. Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaro J, et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther. 2006;11(4):473-82.
42. Angeli E, Mainini A, Cargnel A, Uberti-Foppa C, Orani A, Carbone R, et al. Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection. Curr HIV Res. 2009;7(4):447-55.
43. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81(3):452-8.
44. Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, et al. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res. 2009.
45. Nagaki M, Shimizu M, Sugihara JI, Tomita E, Sano C, Naiki T, et al. Clinical trial: extended treatment duration of peginterferonalpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders. Aliment Pharmacol Ther. 2009;30(4):343-51.
46. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005;43(2):250-7.
47. Ide T, Hino T, Ogata K, Miyajima I, Kuwahara R, Kuhara K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negativestatus in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol. 2009;104(1):70-5.
48. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008;47(1):43-50.
49. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130(4):1086-97.
50. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010;138(2):503-12, 12 e1.
51. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007;46(6):1688-94.
52. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131(2):451-60.
53. Miyase S, Ogata K, Haraoka K, Morishita Y, Fujiyama S. The efficacy of prolonging treatment with peginterferon alfa-2b and ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients HCV RNA positive at week 8 but negative at week 12. Acta Hepato Jpn. 2010;51(1):48-50.
54. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52(4):1201-7.
55. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009(1):MR000006.
56. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
57. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative beforeand-after evaluation. JAMA. 2001;285(15):1992-5.